GLTO

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Galecto Inc

NASDAQ | GLTO

12.75

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 13, 2025)

$16.77M

Market Cap

-

P/E Ratio

-13.07

EPS

$18.45

52 Week High

$2.00

52 Week Low

HEALTHCARE

Sector

GLTO Chart

Recent Chart
Price Action

GLTO Technicals

Tags:

GLTO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$4.4M
Total Revenue $0
Cost Of Revenue $4.4M
Costof Goods And Services Sold $4.4M
Operating Income -$22M
Selling General And Administrative $10M
Research And Development $6.4M
Operating Expenses $18M
Investment Income Net -
Net Interest Income $844K
Interest Income $844K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$21M
Income Tax Expense $41K
Interest And Debt Expense -
Net Income From Continuing Operations -$21M
Comprehensive Income Net Of Tax -
Ebit -$22M
Ebitda -$21M
Net Income -$21M

Revenue & Profitability

Earnings Performance

GLTO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $17M
Total Current Assets $17M
Cash And Cash Equivalents At Carrying Value $14M
Cash And Short Term Investments $14M
Inventory -
Current Net Receivables $881K
Total Non Current Assets $293K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $0
Other Current Assets $1.8M
Other Non Current Assets -
Total Liabilities $1.3M
Total Current Liabilities $1.2M
Current Accounts Payable $377K
Deferred Revenue -
Current Debt -
Short Term Debt $12K
Total Non Current Liabilities $104K
Capital Lease Obligations $73K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $61K
Other Current Liabilities $820K
Other Non Current Liabilities $43K
Total Shareholder Equity $16M
Treasury Stock -
Retained Earnings -$278M
Common Stock -
Common Stock Shares Outstanding $1.2M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$19M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $91K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $12M
Cashflow From Financing $0
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $1.9M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$21M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$4.4M
Total Revenue $0
Cost Of Revenue $4.4M
Costof Goods And Services Sold $4.4M
Operating Income -$22M
Selling General And Administrative $10M
Research And Development $6.4M
Operating Expenses $18M
Investment Income Net -
Net Interest Income $844K
Interest Income $844K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$21M
Income Tax Expense $41K
Interest And Debt Expense -
Net Income From Continuing Operations -$21M
Comprehensive Income Net Of Tax -
Ebit -$22M
Ebitda -$21M
Net Income -$21M

GLTO News

GLTO Profile

Galecto Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Galecto, Inc. is a clinical-stage biotechnology company based in Copenhagen, Denmark, focused on developing innovative therapeutic molecules aimed at addressing significant unmet medical needs in fibrosis, cancer, and inflammation. With a robust pipeline of candidates, Galecto leverages its proprietary galectin technology platform to target pathways involved in disease progression, positioning itself as a promising player in the biopharmaceutical sector. The company's commitment to advancing treatments demonstrates its potential for impactful contributions to patient care and growth in the biotechnology landscape.

VHAI
-25.00%
$0.00
YYAI
-10.47%
$0.17
BURU
+7.74%
$0.51
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
RGTI
+25.02%
$54.91
GWH
+117.54%
$9.05
BITF
+28.33%
$5.39
NVDA
+2.81%
$188.32
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
NVTS
+21.14%
$9.97
INTC
+2.33%
$37.22
JOBY
+3.00%
$16.77
DNN
+6.94%
$3.08
GPUS
-10.39%
$0.43
CAN
+39.44%
$1.52
QBTS
+23.01%
$40.61
TSLA
+5.41%
$435.90
BBD
+0.98%
$3.09
F
+1.13%
$11.54
CLF
+4.93%
$13.83
AXDX
-61.36%
$0.03
NIO
+7.00%
$7.18
QS
+15.57%
$16.98
SOFI
+3.62%
$27.14
CRML
+55.40%
$23.28
ETHD
-12.82%
$3.33
CIFR
+19.85%
$20.34
ACHR
+6.68%
$12.77
RXRX
+3.94%
$5.53
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
APLD
+0.73%
$34.24
TLRY
-1.74%
$1.69
BTBT
+6.38%
$4.00
NAK
+31.03%
$2.66
AMD
+0.40%
$215.76
LAES
+13.30%
$6.13
ONDS
+17.24%
$10.81
DVLT
-10.52%
$1.70
MP
+21.34%
$95.06
USAR
+18.61%
$38.68
RR
+8.95%
$6.45
IREN
+7.31%
$64.14
AVGO
+9.87%
$356.70
UAMY
+36.85%
$16.71
ABAT
+36.59%
$9.22
PFE
-0.20%
$24.73
SNAP
+3.47%
$8.05
NAKA
-1.56%
$0.85
RIG
+3.89%
$3.20
IONQ
+16.19%
$82.09
AAL
+1.90%
$11.74
QUBT
+12.85%
$21.46
UUUU
+16.86%
$23.77
MARA
+8.52%
$20.23
NOK
-1.31%
$5.25
EOSE
+23.37%
$17.05
BMNR
+8.34%
$56.85
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADAP
-2.59%
$0.18
EPWK
-8.00%
$0.08
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AAPL
+0.97%
$247.66
AMZN
+1.71%
$220.07
WULF
+3.62%
$14.00
XCH
+103.41%
$1.68
T
-1.08%
$25.59
HPE
+1.63%
$24.80
RF
+1.65%
$24.56
NB
+8.95%
$11.32
SRM
+53.27%
$10.30
BTG
+4.52%
$5.31
CLSK
+3.94%
$20.04
GDXD
-13.62%
$0.73
BAC
+0.43%
$48.86
QSI
+24.55%
$2.08
KDP
+2.32%
$26.42
RGTZ
-50.00%
$9.30
VALE
+2.41%
$11.01
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
ORCL
-1.34%
$292.95
ABEV
+1.42%
$2.14
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
TMC
+20.31%
$10.69
HOOD
+1.23%
$140.68
TMQ
+10.62%
$6.56
GRAB
+1.19%
$5.93
KDLY
-7.21%
$0.87
GGB
+2.85%
$3.24
ETWO
0.00%
$3.30
VHAI
-25.00%
$0.00
YYAI
-10.47%
$0.17
BURU
+7.74%
$0.51
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
RGTI
+25.02%
$54.91
GWH
+117.54%
$9.05
BITF
+28.33%
$5.39
NVDA
+2.81%
$188.32
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
NVTS
+21.14%
$9.97
INTC
+2.33%
$37.22
JOBY
+3.00%
$16.77
DNN
+6.94%
$3.08
GPUS
-10.39%
$0.43
CAN
+39.44%
$1.52
QBTS
+23.01%
$40.61
TSLA
+5.41%
$435.90
BBD
+0.98%
$3.09
F
+1.13%
$11.54
CLF
+4.93%
$13.83
AXDX
-61.36%
$0.03
NIO
+7.00%
$7.18
QS
+15.57%
$16.98
SOFI
+3.62%
$27.14
CRML
+55.40%
$23.28
ETHD
-12.82%
$3.33
CIFR
+19.85%
$20.34
ACHR
+6.68%
$12.77
RXRX
+3.94%
$5.53
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
APLD
+0.73%
$34.24
TLRY
-1.74%
$1.69
BTBT
+6.38%
$4.00
NAK
+31.03%
$2.66
AMD
+0.40%
$215.76
LAES
+13.30%
$6.13
ONDS
+17.24%
$10.81
DVLT
-10.52%
$1.70
MP
+21.34%
$95.06
USAR
+18.61%
$38.68
RR
+8.95%
$6.45
IREN
+7.31%
$64.14
AVGO
+9.87%
$356.70
UAMY
+36.85%
$16.71
ABAT
+36.59%
$9.22
PFE
-0.20%
$24.73
SNAP
+3.47%
$8.05
NAKA
-1.56%
$0.85
RIG
+3.89%
$3.20
IONQ
+16.19%
$82.09
AAL
+1.90%
$11.74
QUBT
+12.85%
$21.46
UUUU
+16.86%
$23.77
MARA
+8.52%
$20.23
NOK
-1.31%
$5.25
EOSE
+23.37%
$17.05
BMNR
+8.34%
$56.85
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADAP
-2.59%
$0.18
EPWK
-8.00%
$0.08
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AAPL
+0.97%
$247.66
AMZN
+1.71%
$220.07
WULF
+3.62%
$14.00
XCH
+103.41%
$1.68
T
-1.08%
$25.59
HPE
+1.63%
$24.80
RF
+1.65%
$24.56
NB
+8.95%
$11.32
SRM
+53.27%
$10.30
BTG
+4.52%
$5.31
CLSK
+3.94%
$20.04
GDXD
-13.62%
$0.73
BAC
+0.43%
$48.86
QSI
+24.55%
$2.08
KDP
+2.32%
$26.42
RGTZ
-50.00%
$9.30
VALE
+2.41%
$11.01
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
ORCL
-1.34%
$292.95
ABEV
+1.42%
$2.14
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
TMC
+20.31%
$10.69
HOOD
+1.23%
$140.68
TMQ
+10.62%
$6.56
GRAB
+1.19%
$5.93
KDLY
-7.21%
$0.87
GGB
+2.85%
$3.24
ETWO
0.00%
$3.30
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.